Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125996331 | 12599633 | 1 | I | 20160719 | 20160727 | 20160727 | EXP | PHHY2016US100005 | SANDOZ | WALLACE KL, FILIPEK RL, LA HOZ RM, WILLIAMSON JC. SUBTHERAPEUTIC VORICONAZOLE CONCENTRATIONS ASSOCIATED WITH CONCOMITANT DEXAMETHASONE: CASE REPORT AND REVIEW OF THE LITERATURE. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS. 2016;41(4):441-43 | 84.00 | YR | M | Y | 60.00000 | KG | 20160727 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125996331 | 12599633 | 1 | PS | VORICONAZOLE. | VORICONAZOLE | 1 | Intravenous (not otherwise specified) | 6 MG/KG, Q12H | 200265 | 6 | MG/KG | Q12H | |||||||
| 125996331 | 12599633 | 2 | I | VORICONAZOLE. | VORICONAZOLE | 1 | Intravenous (not otherwise specified) | 4 MG/KG, Q12H | 200265 | 4 | MG/KG | Q12H | |||||||
| 125996331 | 12599633 | 3 | I | VORICONAZOLE. | VORICONAZOLE | 1 | Intravenous (not otherwise specified) | 200 MG, Q12H | 200265 | 200 | MG | Q12H | |||||||
| 125996331 | 12599633 | 4 | I | VORICONAZOLE. | VORICONAZOLE | 1 | Oral | 250 MG, Q12H | 200265 | 250 | MG | Q12H | |||||||
| 125996331 | 12599633 | 5 | I | VORICONAZOLE. | VORICONAZOLE | 1 | Intravenous (not otherwise specified) | 300 MG, Q12H | 200265 | 300 | MG | Q12H | |||||||
| 125996331 | 12599633 | 6 | I | VORICONAZOLE. | VORICONAZOLE | 1 | Oral | 300 MG, Q12H | 200265 | 300 | MG | Q12H | |||||||
| 125996331 | 12599633 | 7 | I | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | 4 MG, Q8H | Y | U | 0 | 4 | MG | Q8H | |||||
| 125996331 | 12599633 | 8 | I | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | 3 MG, Q8H | Y | U | 0 | 3 | MG | Q8H | |||||
| 125996331 | 12599633 | 9 | I | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | 2 MG, Q8H | Y | U | 0 | 2 | MG | Q8H | |||||
| 125996331 | 12599633 | 10 | I | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | 1 MG, Q8H | Y | U | 0 | 1 | MG | Q8H | |||||
| 125996331 | 12599633 | 11 | I | DEXAMETHASONE. | DEXAMETHASONE | 1 | Oral | 0.5 MG, Q8H | Y | U | 0 | .5 | MG | Q8H | |||||
| 125996331 | 12599633 | 12 | C | CEFEPIME | CEFEPIME HYDROCHLORIDE | 1 | Unknown | U | 0 | ||||||||||
| 125996331 | 12599633 | 13 | C | VANCOMYCIN | VANCOMYCIN | 1 | Unknown | U | 0 | ||||||||||
| 125996331 | 12599633 | 14 | C | METRONIDAZOLE. | METRONIDAZOLE | 1 | Unknown | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125996331 | 12599633 | 1 | Brain abscess |
| 125996331 | 12599633 | 7 | Brain oedema |
| 125996331 | 12599633 | 12 | Product used for unknown indication |
| 125996331 | 12599633 | 13 | Product used for unknown indication |
| 125996331 | 12599633 | 14 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125996331 | 12599633 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125996331 | 12599633 | Brain abscess | |
| 125996331 | 12599633 | Disease progression | |
| 125996331 | 12599633 | Drug interaction | |
| 125996331 | 12599633 | Drug level below therapeutic |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |